PROCEPT BIOROBOTICS CORP (PRCT)
US74276L1052 - Common Stock
Taking everything into account, PRCT scores 4 out of 10 in our fundamental rating. PRCT was compared to 188 industry peers in the Health Care Equipment & Supplies industry. PRCT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PRCT shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
PRCT had negative earnings in the past year.
PRCT had a negative operating cash flow in the past year.
PRCT had negative earnings in each of the past 5 years.
PRCT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of PRCT (-27.70%) is comparable to the rest of the industry.
PRCT has a Return On Equity (-41.19%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.7% | ||
| ROE | -41.19% | ||
| ROIC | N/A |
ROA(3y)-24.03%
ROA(5y)-36.38%
ROE(3y)-34.78%
ROE(5y)-67.01%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRCT has a Gross Margin of 54.73%. This is comparable to the rest of the industry: PRCT outperforms 47.59% of its industry peers.
The Profit Margin and Operating Margin are not available for PRCT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.73% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PRCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
PRCT has more shares outstanding than it did 1 year ago.
The debt/assets ratio for PRCT has been reduced compared to a year ago.
2.2 Solvency
PRCT has an Altman-Z score of 23.51. This indicates that PRCT is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 23.51, PRCT belongs to the top of the industry, outperforming 94.65% of the companies in the same industry.
A Debt/Equity ratio of 0.20 indicates that PRCT is not too dependend on debt financing.
The Debt to Equity ratio of PRCT (0.20) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 23.51 |
ROIC/WACCN/A
WACC9.04%
2.3 Liquidity
A Current Ratio of 7.51 indicates that PRCT has no problem at all paying its short term obligations.
With an excellent Current ratio value of 7.51, PRCT belongs to the best of the industry, outperforming 85.56% of the companies in the same industry.
PRCT has a Quick Ratio of 6.49. This indicates that PRCT is financially healthy and has no problem in meeting its short term obligations.
PRCT has a better Quick ratio (6.49) than 85.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.51 | ||
| Quick Ratio | 6.49 |
3. Growth
3.1 Past
PRCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.72%, which is quite good.
Looking at the last year, PRCT shows a very strong growth in Revenue. The Revenue has grown by 71.71%.
The Revenue has been growing by 160.32% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)13.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.57%
Revenue 1Y (TTM)71.71%
Revenue growth 3Y160.32%
Revenue growth 5YN/A
Sales Q2Q%66.29%
3.2 Future
PRCT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.27% yearly.
Based on estimates for the next years, PRCT will show a very strong growth in Revenue. The Revenue will grow by 32.94% on average per year.
EPS Next Y20.77%
EPS Next 2Y18.01%
EPS Next 3Y18%
EPS Next 5Y16.27%
Revenue Next Year65.98%
Revenue Next 2Y52.76%
Revenue Next 3Y45.49%
Revenue Next 5Y32.94%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PRCT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PRCT's earnings are expected to grow with 18.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.01%
EPS Next 3Y18%
5. Dividend
5.1 Amount
No dividends for PRCT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROCEPT BIOROBOTICS CORP
NASDAQ:PRCT (11/22/2024, 8:00:00 PM)
After market: 93.6 0 (0%)93.6
-0.85 (-0.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.06B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.7% | ||
| ROE | -41.19% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.73% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.51 | ||
| Quick Ratio | 6.49 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)13.72%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y20.77%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)71.71%
Revenue growth 3Y160.32%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y